Scientific Publications
Newest First
All Years
Multi-MOA of EYP-1901 for Retinal Diseases
Clinical Trials at the Summit
Exploring New Horizons in Retina: EYP-1901-Sustained Drug Delivery in Wet AMD and DME
Pacific Retina Club Symposium, 2026
VERONA phase 2 clinical trial of bioerodible EYP-1901 (vorolanib intravitreal insert) versus aflibercept for diabetic macular edema (DME): Visual, anatomic, and angiographic outcomes
ARVO 2026 Annual Meeting
DAVIO 2 Phase 2 Trial: Vision Outcomes with Bioerodible EYP-1901 (vorolanib intravitreal insert) Versus Aflibercept in Wet Age-Related Macular Degeneration (wAMD)
ARVO 2026 Annual Meeting
Development of EYP-1901, a bioerodible intravitreal insert for sustained release of the tyrosine kinase inhibitor vorolanib for retinal exudative disease
ARVO 2026 Annual Meeting
COMO and CAPRI trial design: Pivotal phase 3 non-inferiority studies of EYP-1901 vs on-label aflibercept in diabetic macular edema
ARVO 2026 Annual Meeting
Vorolanib inhibition of IL-6 signaling: A novel multi-mechanism of action for EYP-1901 in retinal exudative diseases
ARVO 2026 Annual Meeting
DAVIO 2 phase 2 trial of bioerodible EYP-1901 (vorolanib intravitreal insert) for wet age-related macular degeneration: Results in subgroup that met LUGANO/LUCIA phase 3 inclusion criteria
ARVO 2026 Annual Meeting
Practice Economics and Considerations for Intravitreal Medications in 2025/2026
Sunshine Eye & Retina, 2026
Exploring New Horizons in Retina: EYP-1901 and the Path to Durable Outcomes for Patients
COPHy, 2026
